{
  "question_stem": {
    "en": "A 52-year-old man comes to the office for a follow-up appointment. Four years ago, the patient experienced a small intracerebral hemorrhage due to uncontrolled hypertension; he had multiple seizures after the stroke, and treatment with phenytoin was initiated. The seizures are well controlled with the medication, but attempts at tapering therapy have led to recurrent seizures. The patient has mild residual weakness of the left side but can perform daily activities without difficulty. He is adherent with antiepileptic and antihypertensive treatments. Vital signs are within normal limits and physical examination is unremarkable except mild left hemiparesis. Laboratory studies reveal a decreased serum level of 25-hydroxyvitamin D. Which of the following effects of the antiseizure medication on vitamin D metabolism best explains this patient's laboratory findings?",
    "zh": "一名52岁男性前来就诊复诊。四年前，患者因高血压控制不佳而发生小脑出血；卒中后出现多次癫痫发作，并开始使用苯妥英钠治疗。癫痫发作已得到药物的良好控制，但尝试减量治疗导致癫痫复发。患者左侧肢体轻度残留无力，但可以无困难地进行日常活动。他依从抗癫痫和降压治疗。生命体征在正常范围内，体格检查无特殊，仅见轻度左侧轻偏瘫。实验室检查显示血清25-羟基维生素D水平降低。以下哪种抗癫痫药物对维生素D代谢的影响最能解释该患者的实验室检查结果？"
  },
  "question": {
    "en": "Which of the following effects of the antiseizure medication on vitamin D metabolism best explains this patient's laboratory findings?",
    "zh": "以下哪种抗癫痫药物对维生素D代谢的影响最能解释该患者的实验室检查结果？"
  },
  "options": {
    "A": {
      "en": "Decreased production of plasma-binding proteins",
      "zh": "血浆结合蛋白产生减少"
    },
    "B": {
      "en": "Decreased ultraviolet B-induced epidermal synthesis",
      "zh": "紫外线B诱导的表皮合成减少"
    },
    "C": {
      "en": "Formation of nonabsorbable complexes in the intestinal lumen",
      "zh": "在肠腔内形成不可吸收的复合物"
    },
    "D": {
      "en": "Increased catabolism by hepatic microsomal enzymes",
      "zh": "肝微粒体酶分解代谢增加"
    },
    "E": {
      "en": "Inhibition of activating enzymes in the renal tubular cells",
      "zh": "肾小管细胞中活化酶的抑制"
    }
  },
  "correct_answer": "D",
  "explanation": {
    "en": "Several antiepileptic medications (eg, phenytoin, carbamazepine, phenobarbital) are strong inducers of cytochrome P-450 (CYP) enzymes. This effect is responsible for notable drug interactions due to increased clearance of certain pharmaceutical agents (eg, warfarin).\n\nIn addition, these medications, especially phenytoin, induce CYP24 (ie, 25-hydroxyvitamin D-24-hydroxylase), which converts 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D (inactive form). As a result, there is less 25-dihydroxyvitamin D available for conversion to 1,25-dihydroxyvitamin D (active form). Deficiency of 1,25-dihydroxyvitamin D leads to decreased intestinal absorption of calcium. The resulting compensatory increase in parathyroid hormone secretion causes increased release of calcium from bones and progressive loss of bone mineral density.\n\n(Choice A) Vitamin D-binding protein (VDBP) carries a large share of circulating vitamin D metabolites. Patients with low levels of VDBP due to decreased synthesis (eg, hepatic dysfunction) or excessive renal losses (eg, nephrotic syndrome) have low measured levels of 25-hydroxyvitamin D. However, phenytoin does not affect VDBP synthesis.\n\n(Choice B) Melanin absorbs ultraviolet B light, which is required for vitamin D synthesis in the epidermis. Melanin pigmentation can affect epidermal vitamin D production, but phenytoin does not impact epidermal vitamin D synthesis.\n\n(Choice C) Some medications (eg, antacids) can form nonabsorbable complexes with micronutrients and other medications in the intestinal lumen, leading to decreased absorption. However, decreased absorption of vitamin D typically occurs due to fat malabsorption (eg, intestinal or biliopancreatic disease) rather than formation of insoluble complexes.\n\n(Choice E) 25-hydroxyvitamin D is converted to active 1,25-dihydroxyvitamin D by 1-alpha hydroxylase in renal tubular cells. This enzyme is inhibited by fibroblast growth factor-23, which also increases activity of 24-alpha-hydroxylase (inactivating enzyme). Phenytoin does not affect 1-alpha hydroxylase activity.\n\nEducational objective:\nPhenytoin and other antiepileptic medications are inducers of cytochrome P-450 (CYP) enzymes, including CYP24, which converts 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D (inactive form). As a result, there is less 25-hydroxyvitamin D available for conversion to 1,25-dihydroxyvitamin D (active form), leading to deficiency.",
    "zh": "一些抗癫痫药物（例如，苯妥英钠、卡马西平、苯巴比妥）是细胞色素P-450 (CYP) 酶的强诱导剂。这种作用是由于某些药物（例如，华法林）的清除率增加而导致明显的药物相互作用。\n\n此外，这些药物，特别是苯妥英钠，诱导 CYP24（即 25-羟基维生素D-24-羟化酶），将 25-羟基维生素D转化为 24,25-二羟基维生素D（非活性形式）。因此，可用于转化为 1,25-二羟基维生素D（活性形式）的 25-二羟基维生素D减少。1,25-二羟基维生素D缺乏导致钙的肠道吸收减少。由此产生的代偿性甲状旁腺激素分泌增加导致骨骼中钙的释放增加和骨矿物质密度的进行性降低。\n\n（选项A）维生素D结合蛋白 (VDBP) 携带大部分循环的维生素D代谢物。由于合成减少（例如，肝功能障碍）或过度肾脏损失（例如，肾病综合征）导致VDBP水平低的患者，其测得的25-羟基维生素D水平较低。然而，苯妥英钠不影响VDBP的合成。\n\n（选项B）黑色素吸收紫外线B光，这是表皮中维生素D合成所必需的。黑色素色素沉着会影响表皮维生素D的产生，但苯妥英钠不影响表皮维生素D的合成。\n\n（选项C）一些药物（例如，抗酸药）可以在肠腔内与微量营养素和其他药物形成不可吸收的复合物，导致吸收减少。然而，维生素D吸收减少通常是由于脂肪吸收不良（例如，肠道或胆胰疾病），而不是形成不溶性复合物。\n\n（选项E）25-羟基维生素D通过肾小管细胞中的 1-α 羟化酶转化为活性 1,25-二羟基维生素D。这种酶被成纤维细胞生长因子-23 抑制，后者也增加 24-α-羟化酶（失活酶）的活性。苯妥英钠不影响 1-α 羟化酶活性。\n\n教育目标：\n苯妥英钠和其他抗癫痫药物是细胞色素P-450 (CYP) 酶的诱导剂，包括 CYP24，它将 25-羟基维生素D转化为 24,25-二羟基维生素D（非活性形式）。因此，可用于转化为 1,25-二羟基维生素D（活性形式）的 25-羟基维生素D减少，导致缺乏。"
  },
  "summary": {
    "en": "This question tests knowledge of the mechanism by which phenytoin, an antiepileptic drug, affects vitamin D metabolism, leading to decreased levels of 25-hydroxyvitamin D. It requires understanding of enzyme induction and its impact on vitamin D conversion. \n\nThe key to solving this question is recognizing that phenytoin is a CYP450 inducer, specifically CYP24, which leads to increased catabolism of 25-hydroxyvitamin D into an inactive form. This reduces the availability of 25-hydroxyvitamin D for conversion to the active form, 1,25-dihydroxyvitamin D.",
    "zh": "本题考察对苯妥英钠（一种抗癫痫药物）影响维生素D代谢机制的理解，从而导致25-羟基维生素D水平降低。它需要了解酶诱导及其对维生素D转化的影响。\n\n解决此问题的关键是认识到苯妥英钠是 CYP450 诱导剂，特别是 CYP24，这会导致 25-羟基维生素D分解代谢增加，转化为非活性形式。这降低了 25-羟基维生素D转化为活性形式 1,25-二羟基维生素D的可用性。"
  },
  "tags": "Phenytoin; Vitamin D deficiency; Cytochrome P-450; Enzyme induction; Antiepileptic drugs; Neurology; Endocrinology; 25-hydroxyvitamin D; CYP24",
  "category": "Neuro",
  "question_id": "14044",
  "has_exhibits": true,
  "exhibit_count": 1,
  "exhibit_files": [
    "image1.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Neuro 23\\14044",
  "extracted_at": "2025-11-05T15:16:00.486691",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:19:28.834562",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}